Bridgeway Capital Management’s Apyx Medical APYX Stock Holding History

Bridgeway Capital Management’s Portfolio APYX Stock Details APYX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$277K	Hold	61,601	–	–	﹤0.01%	995
2026 Q1	$227K	Hold	61,601	–	–	﹤0.01%	1004
2025 Q4	$216K	Hold	61,601	–	–	﹤0.01%	1002
2025 Q3	$132K	Hold	61,601	–	–	﹤0.01%	1073
2025 Q2	$139K	Sell	61,601 -30,000	-33%	-$42.2K	﹤0.01%	1025
2025 Q1	$125K	Sell	91,601 -45,799	-33%	-$63.1K	﹤0.01%	999
2024 Q4	$217K	Sell	137,400 -3,000	-2%	-$4.2K	﹤0.01%	985
2024 Q3	$174K	Hold	140,400	–	–	﹤0.01%	1094
2024 Q2	$188K	Sell	140,400 -22,700	-14%	-$33.5K	﹤0.01%	1067
2024 Q1	$222K	Hold	163,100	–	–	﹤0.01%	1090
2023 Q4	$427K	Hold	163,100	–	–	0.01%	976
2023 Q3	$522K	Hold	163,100	–	–	0.01%	861
2023 Q2	$820K	Sell	163,100 -30,000	-16%	-$152K	0.02%	777
2023 Q1	$556K	Sell	193,100 -100,000	-34%	-$292K	0.01%	860
2022 Q4	$686K	Buy	293,100 +181,300	+162%	+$553K	0.02%	818
2022 Q3	$502K	Buy	+111,800	New	+$801K	0.01%	896
2021 Q3	–	Sell	-10,300	Closed	-$106K	–	1286
2021 Q2	$106K	Sell	10,300 -14,700	-59%	-$146K	﹤0.01%	1309
2021 Q1	$242K	Hold	25,000	–	–	﹤0.01%	1261
2020 Q4	$180K	Buy	+25,000	New	+$166K	﹤0.01%	1221
2020 Q2	–	Sell	-60,070	Closed	-$216K	–	1300
2020 Q1	$216K	Sell	60,070 -35,800	-37%	-$240K	﹤0.01%	1033
2019 Q4	$811K	Sell	95,870 -44,200	-32%	-$319K	0.01%	796
2019 Q3	$948K	Sell	140,070 -25,000	-15%	-$177K	0.01%	738
2019 Q2	$1.11M	Buy	165,070 +25,000	+18%	+$136K	0.01%	702
2019 Q1	$884K	Sell	140,070 -16,400	-10%	-$127K	0.01%	803
2018 Q4	$1.01M	Hold	156,470	–	–	0.01%	724
2018 Q3	$1.11M	Hold	156,470	–	–	0.01%	842
2018 Q2	$681K	Hold	156,470	–	–	0.01%	1031
2018 Q1	$465K	Hold	156,470	–	–	0.01%	1115
2017 Q4	$407K	Hold	156,470	–	–	﹤0.01%	1151
2017 Q3	$529K	Buy	156,470 +90,000	+135%	+$232K	0.01%	1076
2017 Q2	$164K	Hold	66,470	–	–	﹤0.01%	1320
2017 Q1	$177K	Buy	+66,470	New	+$221K	﹤0.01%	1295

Other funds holding APYX

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

ACM

Archon Capital Management Seattle, Washington $246M AUM 130.69% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

EIM

Essex Investment Management Boston, Massachusetts $763M AUM 108.51% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

SBCM

Silverberg Bernstein Capital Management Armonk, New York $261M AUM 89.93% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

HKAM

Horizon Kinetics Asset Management New York $8.82B AUM 23.05% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bridgeway Capital Management's APYX Position: Q2 2026 in Review

Bridgeway Capital Management held its Apyx Medical (APYX) position steady in Q2 2026 at 61,601 shares worth $277K. The position accounts for ﹤0.01% of the portfolio, ranked #995.

Bridgeway Capital Management first reported a position in APYX in Q1 2017 and has held it in 32 quarters since. The position peaked at $1.11M in Q3 2018. 68 funds tracked by Wall St. Rank hold APYX as of Q2 2026.

Bridgeway Capital Management held 61,601 shares of Apyx Medical worth $277K as of Q2 2026.
Bridgeway Capital Management left its Apyx Medical share count unchanged in Q2 2026.
Apyx Medical made up ﹤0.01% of Bridgeway Capital Management's portfolio in Q2 2026, its #995 holding.
Bridgeway Capital Management first reported a position in Apyx Medical in Q1 2017 and has held it in 32 quarters since.
Bridgeway Capital Management's Apyx Medical position peaked at $1.11M in Q3 2018.
68 funds tracked by Wall St. Rank held Apyx Medical as of Q2 2026.

Based on Bridgeway Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.